$3.29 1.2%
LGVN Stock Price vs. AI Score (Last 150 days)
Data gathered: July 21

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Longeveron

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.


Longeveron
Price $3.29
Target Price Sign up
Volume 2,550,000
Market Cap $32M
Year Range $0.82 - $23.7
Dividend Yield 0%
Revenue per Employee $51,474
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24550,000220,000330,000-4.1M-3.8M0.000
Q4 '2363,00065,000-2,000-6M-4.7M-0.250
Q3 '23150,00096,00054,000-5.1M-5.1M-0.280
Q2 '23220,000120,00093,000-5.6M-5.6M-0.270
Q1 '23280,000200,00076,000-4.6M-4.6M-0.220

Insider Transactions View All

Soffer Rock filed to buy 31,915 shares at $0.1.
April 12 '24
Hashad Mohamed Wa'el Ahmed filed to buy 10,638 shares at $0.1.
April 12 '24
Hare Joshua filed to buy 42,553 shares at $0.1.
April 12 '24
Soffer Rock filed to buy 106,383 shares at $0.1.
April 12 '24
Hare Joshua filed to buy 106,383 shares at $0.1.
April 12 '24

What is the Market Cap of Longeveron?

The Market Cap of Longeveron is $32M.

How Many People Work at Longeveron?

As of our latest update, Longeveron employed approximately 19 people worldwide. However, it's important to note that Longeveron's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Longeveron's revenue per employee?

$51,474. To calculate Longeveron's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Longeveron?

Currently, the price of one share of Longeveron stock is $3.29.

How can I analyze the LGVN stock price chart for investment decisions?

The LGVN stock price chart above provides a comprehensive visual representation of Longeveron's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Longeveron shares. Our platform offers an up-to-date LGVN stock price chart, along with technical data analysis and alternative data insights.

Does LGVN offer dividends to its shareholders?

As of our latest update, Longeveron (LGVN) does not offer dividends to its shareholders. Investors interested in Longeveron should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Longeveron?

Some of the similar stocks of Longeveron are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.